No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NSPR InspireMD
- 2.930
- +0.470+19.11%
Close Jul 24 16:00 ET
- 2.850
- -0.080-2.73%
Post 16:09 ET
73.99MMarket Cap-5860P/E (TTM)
2.950High2.401Low65.71KVolume2.450Open2.460Pre Close179.44KTurnover0.68%Turnover RatioLossP/E (Static)25.25MShares3.85052wk High2.11P/B28.41MFloat Cap1.81052wk Low--Dividend TTM9.69MShs Float75862432.808Historical High--Div YieldTTM22.34%Amplitude0.806Historical Low2.730Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
InspireMD Brings in $17.9M to Support Stent Trial
InspireMD Secures Funds to Expand Healthcare Innovations
Express News | InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
Express News | InspireMD: Files Prospectus Supplement to Offer, Sell Common Stock of up to $17 Mln From Time to Time Under Equity Distribution Deal With Piper Sandler
InspireMD's CGuard Stent Shows Promise in C-GUARDIANS Trial
Express News | InspireMD Presents One-Year Follow-Up Results From C-GUARDIANS US IDE Trial Of CGuard At LINC 2024 On May 28 At 8:53 A.m. EDT
Comments
$InspireMD(NSPR.US$ the mesh stint will become FDA approved. When is the question.
$InspireMD(NSPR.US$ InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
$InspireMD(NSPR.US$ InspireMD Inc -U.S. Commercial Launch of Cguard™ Prime Carotid Stent System Anticipated in H1 2025, IF Approved
$InspireMD(NSPR.US$ INSPIREMD INC -STUDY RESULTS TO SUPPORT A PREMARKET APPROVAL (PMA) APPLICATION TO FDA IN H2 2024
Reuters05/28/2024 08:53
Reuters05/28/2024 08:53
$InspireMD(NSPR.US$ InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.511 billion which beat the analyst consensus estimate of $1.384 million by 109.08K percent. This is a 121.85K percent increase over sales of $1.239 million the same period...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg